Literature DB >> 18651339

Improvement of subjective well-being and enduring symptomatic remission, a 5-year follow-up of first episode schizophrenia.

L de Haan1, L van Nimwegen, T van Amelsvoort, P Dingemans, D Linszen.   

Abstract

INTRODUCTION: The aim of this prospective study was to compare the predictive validity of early improvement of subjective experience and early improvement of rater assessed symptoms on enduring symptomatic remission (ESR) status during 5 years follow.
METHODS: 110 consecutively admitted patients suffering from a first episode of schizophrenia or related disorders were investigated. We defined early improvement of subjective well-being as a delta-score of the total Subjective Well-being under Neuroleptics scale-20 item version (SWN-K) at admission and after 6 weeks treatment. The severity of psychopathology was assessed with the Positive and Negative Syndrome Scale (PANSS) at admission, 6 weeks, 6 months, 3 and 5 years after admission. Enduring symptomatic remission (ESR) was defined as complying to the symptomatic remission criteria at PANSS assessment at 6 months and 5 years and continuing this state between 6 months and 5 years follow-up. Paired-samples and independent t-test were used to compare means.
RESULTS: Patients with ESR (n=30) had a higher mean improvement of subjective well-being during early treatment as assessed with the SWN-K than those without ESR (n=74) (p=0.004). Early symptomatic improvement as assessed with the PANSS was not related to ESR (p=0.95). DISCUSSION: Early improvement of subjective well-being is related to ESR in first episode schizophrenia or related disorders.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18651339     DOI: 10.1055/s-2008-1076729

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  11 in total

Review 1.  Revisiting the Concept of Subjective Tolerability to Antipsychotic Medications in Schizophrenia and its Clinical and Research Implications: 30 Years Later.

Authors:  A George Awad
Journal:  CNS Drugs       Date:  2019-01       Impact factor: 5.749

2.  The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians.

Authors:  Dieter Naber; Martin Lambert
Journal:  CNS Drugs       Date:  2009-08       Impact factor: 5.749

3.  The relationship, structure and profiles of schizophrenia measurements: a post-hoc analysis of the baseline measures from a randomized clinical trial.

Authors:  Lei Chen; Glenn Phillips; Joseph Johnston; Bruce J Kinon; Haya Ascher-Svanum; Sara Kollack-Walker; Paul Succop; Dieter Naber
Journal:  BMC Psychiatry       Date:  2011-12-28       Impact factor: 3.630

4.  Antipsychotic agents: efficacy and safety in schizophrenia.

Authors:  Arão Nogueira de Araújo; Eduardo Pondé de Sena; Irismar Reis de Oliveira; Mario F Juruena
Journal:  Drug Healthc Patient Saf       Date:  2012-11-29

Review 5.  Remission in schizophrenia: validity, frequency, predictors, and patients' perspective 5 years later.

Authors:  Martin Lambert; Anne Karow; Stefan Leucht; Benno G Schimmelmann; Dieter Naber
Journal:  Dialogues Clin Neurosci       Date:  2010       Impact factor: 5.986

6.  Subjective Well-Being Under Neuroleptics Scale short form (SWN-K): reliability and validity in an Estonian speaking sample.

Authors:  Liina Haring; René Mõttus; Peeter Jaanson; Raine Pilli; Kairi Mägi; Eduard Maron
Journal:  Ann Gen Psychiatry       Date:  2013-09-11       Impact factor: 3.455

7.  The assessment of quality of life in clinical practice in patients with schizophrenia.

Authors:  Anne Karow; Linus Wittmann; Daniel Schöttle; Ingo Schäfer; Martin Lambert
Journal:  Dialogues Clin Neurosci       Date:  2014-06       Impact factor: 5.986

8.  Preliminary data concerning the reliability and psychometric properties of the Greek translation of the 20-item Subjective Well-Being Under Neuroleptic Treatment Scale (SWN-20).

Authors:  Melina Siamouli; Katerina Moutou; Eleonora Pantoula; Stamatia Magiria; Irini Chatzivasileiou; Konstantinos Arapidis; Achileas Chatzivasileiou; Simeon Deres; Konstantinos N Fountoulakis
Journal:  Ann Gen Psychiatry       Date:  2009-01-21       Impact factor: 3.455

9.  Relationship between cognitive insight and subjective quality of life in outpatients with schizophrenia.

Authors:  Jong-Hoon Kim; Seul Lee; Ah-Young Han; Kyungwook Kim; Jinyoung Lee
Journal:  Neuropsychiatr Dis Treat       Date:  2015-08-07       Impact factor: 2.570

10.  Psychiatrists' perceptions of the clinical importance, assessment and management of patient functioning in schizophrenia in Europe, the Middle East and Africa.

Authors:  Philip Gorwood; Tom Burns; Georg Juckel; Alessandro Rossi; Luis San; Ludger Hargarter; Andreas Schreiner
Journal:  Ann Gen Psychiatry       Date:  2013-03-26       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.